Key Takeaways for Illumina Stock as of August 2026
- Six-Month Surge: Illumina stock (ILMN) has climbed 82% since early March, closing at $223.22 on August 24 after three straight quarters of Street target increases built on accelerating clinical demand.
- Street Split: The current tally stands at 6 buys, 4 outperforms, 6 holds, 3 underperforms, and 1 sell, with a $199 mean target that now sits 11% below the stock’s price.
- Model Gap: TIKR’s mid-case model puts fair value at $259 by late 2030, a total return of just 16% and an annualized rate of 4% from here.
- Index Watch: A possible S&P 500 promotion is adding speculative fuel on top of the fundamental run.
Why Illumina Stock’s Clinical Wave Turned Into an 82% Run
Illumina (ILMN) stock has gained 82% since early March, a 230% annualized pace that has carried shares from roughly $122 to $223.22 by August 24. The move did not come from a single headline. It came from three consecutive quarters of guidance raises, each one confirming that clinical sequencing demand was not the one-time bump some investors feared.
The clearest evidence sits in the Q2 2026 print on July 30, when Illumina posted revenue of $1.16 billion, up 9.5% and ahead of the $1.13 billion analysts expected. Management raised full-year revenue guidance to $4.60 billion to $4.64 billion from $4.52 billion to $4.62 billion and lifted its non-GAAP EPS outlook to $5.30 to $5.40 from $5.15 to $5.30, while placing more than 95 NovaSeq X instruments in the quarter alone. Clinical consumables growth, the company’s core profit engine, moved to a mid-teens pace.
Asked whether that clinical strength could keep compounding into 2027, CEO Jacob Thaysen dismissed the idea that a slowdown was coming: “Talking about the clinical cliff, I agree, it’s not a cliff. It’s a wave, and we are surfing it.” That confidence is what the market has been pricing since spring, not a single quarter’s beat.
Illumina stock’s rally reflects a business that kept beating its own raised bar, not a one-time catalyst. That distinction matters, because it means the next leg depends on whether clinical demand keeps accelerating at this pace or simply holds it.
An S&P 500 Promotion Would Add a New Kind of Buyer to Illumina Stock
The rally has a second, more speculative tailwind. With Electronic Arts’ buyout closing on August 4 and opening a slot in the S&P 500, a Reuters report flagged Illumina, currently the largest member of the S&P MidCap 400, as a leading candidate for promotion, particularly in a scenario where the index committee pairs the move with Resideo’s ADI Global Distribution spinoff. Index inclusion would force passive funds to buy shares regardless of valuation, layering a mechanical bid on top of the fundamental one. Nothing has been confirmed, but the speculation alone has kept buyers engaged even as the stock’s multiple has stretched.
Illumina Stock’s Street Coverage Hasn’t Kept Pace With the Rally
Analysts covering Illumina stock currently carry 6 buys, 4 outperforms, 6 holds, 3 underperforms, and 1 sell, drawn from 19 analysts publishing price targets. The mean target sits at $199, which is 11% below the August 24 close of $223.22, a rare case of the Street’s own number trailing the tape rather than leading it.
The trend explains how that gap opened. Back on March 29, the mean target stood at $136.11 against a $117.67 close, putting the Street 16% above the price. By June 28, the stock had jumped to $176.55 while the target rose to only $151.68, flipping the relationship to a 14% discount.
Analysts have kept raising the number since, up 31% from June to August, but Illumina stock’s price moved even faster over the same stretch, so the gap never closed. Buy ratings have also slipped, from 8 in March to 6 now, even as the dollar target climbed.
That pattern lines up with the earnings story in the prior section: the Street believes the fundamentals improved, but not by enough to justify paying $223 for a stock whose average target still sits closer to $199.
TIKR Values Illumina Stock at $259, a Muted 16% Return From Here
TIKR’s mid-case model values Illumina at $259 by late 2030, implying a 16% total return from the current price of $223.22, or an annualized rate of 4% over roughly 4.3 years.
A 4% annualized forward return is a modest ask for a stock that just gained 82% in six months, well below what most equity investors target over a multiyear hold.
That gap between the model’s own long-term earnings algorithm and the price the market is now paying tells the same story as the Street’s below-price mean target: the re-rating built on three quarters of raised guidance and a wave of clinical demand has already been absorbed into the share price, leaving the model with comparatively little room to run from current levels.
Accordingly, ILMN stock’s P/E multiples backs that up. Illumina stock’s NTM price-to-normalized-earnings ratio has jumped from 23x on March 29 to 39x on August 24, a 70% expansion in the multiple itself over the same stretch the stock gained 82%.
That means most of the run came from investors paying more for each dollar of forward earnings, not from the earnings estimates rising to meet the price, which is exactly the kind of re-rating TIKR’s model treats as largely spent.
Should You Invest in Illumina, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Illumina, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Illumina, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ILMN stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
